Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

Asher Biotherapeuticsannounced that it has entered into a clinical trial collaboration and supply agreement with Merck for a planned Phase Ia/Ib dose escalation and expansion trial to evaluate AB248, Asher Bio’s novel investigational CD8-targeted interleukin 2.